Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

News release details

Blueprint Medicines to Present at Upcoming Investor Conferences in February

February 7, 2019 at 4:01 PM EST

CAMBRIDGE, Mass., Feb. 7, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced its participation in the following upcoming investor conferences:

  • Guggenheim Healthcare Talks Idea Forum | Oncology Day in New York, NY on Thursday, February 14, 2019 at 11:30 a.m. ET.
  • 8th Annual SVB Leerink Partners Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 1:00 p.m. ET.


A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at A replay of the webcasts will be archived on Blueprint Medicines' website for 30 days following each presentation.

About Blueprint Medicines

Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We are currently advancing four investigational medicines in clinical development, along with multiple research programs. For more information, visit and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:

SOURCE Blueprint Medicines

Jim Baker, 617-844-8236,